Briacell Therapeutics Corp.

Ordinary Shares International Reporting
Verified Company Profile 11/03/2017
Contact Info
  • 820 Heinz Avenue
  • Berkeley, CA 94710

Business Description

Financial Reporting/Disclosure
Reporting Status International Reporting: TSX Venture Exchange
Audited Financials Audited
Latest Report Apr 30, 2017 Interim Financial Report
CIK 0001610820
Fiscal Year End 7/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: British Columbia, Canada
Year of Inc. 2006
Employees 12 a/o May 06, 2015
Company Officers/Contacts
William V. Williams, MD CEO
Gadi Levin CFO
Farrah Dean VP, Corp. Dev.
Company Directors
Dr. Saeid Babaei Chairman
William V. Williams, MD
Martin Schmieg
Rahoul Sharan
Dr. Charles Wiseman
Company Notes
  • Formerly=Ansell Capital Corp. until 12-2014
Service Providers
Accounting/Auditing Firm
Meyers Norris Penny, LLP
900- 50 Burnhamthorpe Road West
Sussex Centre
Mississauga, ONT, L5B3C2

Legal Counsel
Kilpatrick Townsend & Stockton LLP
607 14th Street NW
Suite 900
Washington, DC, 20005-2018
United States

Bennett Jones LLP
3400 One First Canadian Place
Toronto, ONT, M5X 1A4

Investor Relations Firm
Not Available
BCTXF Security Details
Share Structure
Market Value1 $9,951,700 a/o Nov 22, 2017
Authorized Shares Unlimited a/o Jun 15, 2015
Outstanding Shares 91,300,000 a/o Dec 27, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 72,270,000 a/o Dec 27, 2016
Par Value No Par Value
Transfer Agent(s) Verified by Transfer Agent
Shareholders of Record 33 a/o Jun 15, 2015
Non US Stock Exchange Listing
BCT - TSX Venture Exchange - Qualified
Short Selling Data
Short Interest 10,952 (-66.76%)
Oct 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security